VivoSeq
Oncology

Epithelial Ovarian Cancer

13

Pipeline Programs↗

7

Active Trials↗

12

Companies Involved↗

Epithelial Ovarian Cancer is an emerging landscape with 13 programs across 12 companies. The most active players are Shanghai Gynecologic Oncology Group, Sichuan Baili Pharmaceutical Co., Ltd., Eli Lilly. 9 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

43/100

Pipeline Velocity

19/100

Mech. Concentration

17/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Shanghai Gynecologic Oncology Group

1 program

Phase 1S

Sichuan Baili Pharmaceutical Co., Ltd.

3 programs

Phase 3Eli Lilly logo

Eli Lilly

1 program

Phase 3Teva logo

Teva

1 program

Phase 3M

Meitheal

1 program

Phase 3A

Avyxa

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

85%

Small molecule

11 of 13 classified programs — the dominant modality here.

15%ALL OTHERSMonoclonal antibody215%

Small molecule leads; the ring shows all 13 classified programs, each share of the total. Modality classified for 93% of 15 pipeline programs.

Analysis

Trial Status

7

clinical trials

Recruiting4 · 57%
Not yet recruiting3 · 43%

Clinical Trials

Trial Activity

7 trials

Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors
Recruiting·Genmab logoGenmab·Preclinical·NCT05579366·884 enrolled
A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer
Recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 3·NCT06994195·450 enrolled
A Randomized Phase 3 Trial Evaluating the Safety & Efficacy of IP IMNN-001 Administered in Combination w/ Standard Neoadjuvant & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
Recruiting·IImunon·Phase 3·NCT06915025·500 enrolled
The Feasibility, Safety, and Clinical Outcomes of Fasting During Neoadjuvant Chemotherapy in Patients With Epithelial Ovarian Cancer
Recruiting·CCase Comprehensive Cancer Center·Preclinical·NCT06386887·20 enrolled
A Post-Marketing Surveillance to Evaluate the Safety and Effectiveness of Mirvetuximab Soravtansine-gynx in Patients With Folate Receptor-Alpha Positive, Platinum-Resistant, High-grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Not yet recruiting·AbbVie logoAbbVie·N/A·NCT07687602·69 enrolled
IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer: A Phases Ib, Single Arm Study
Not yet recruiting·SShanghai Gynecologic Oncology Group·Phase 1·NCT07674615·19 enrolled
A Phase III Randomized Controlled Clinical Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
Not yet recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 3·NCT07545460·404 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)